
Opinion|Videos|June 21, 2024
Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape
Key opinion leaders provide a concise overview of the atopic dermatitis (AD) treatment landscape, focusing on the role of topical therapy, and highlight the current unmet needs in AD management.
Advertisement
Episodes in this series

- Provide a brief overview of the treatment landscape, and where topical therapies and systemic therapies fit into this landscape. What are the current unmet needs from your perspective?
- Please incorporate a discussion of the following topical therapies:
- Corticosteroids
- Crisaborole –
AD-301/AD-302 ,CrisADe CARE 1 - Ruxolitinib – TRuE-AD1/TRuE-AD2 –
original publication ,long-term follow up
Advertisement
Related to this article

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.

Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.

Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.

Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5

